Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.31 +4.5%	$1.86	$0.40 ▼ $3.10	$178.17M	2.11	2.17 million shs	1.97 million shs
EDIT Editas Medicine	$2.12 -3.2%	$1.74	$0.91 ▼ $6.05	$183.33M	2.1	2.55 million shs	2.31 million shs
FDMT 4D Molecular Therapeutics	$4.07 -0.2%	$3.68	$2.24 ▼ $28.93	$189.01M	2.84	816,308 shs	229,814 shs
LIAN LianBio	$0.42 +1.2%	$0.30	$0.27 ▼ $4.99	$45.39M	0.23	1.04 million shs	5.28 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+4.52%	+9.48%	+8.45%	+267.72%	+90.91%
EDIT Editas Medicine	-3.20%	-9.79%	+28.48%	+69.60%	-55.93%
FDMT 4D Molecular Therapeutics	-0.25%	-0.49%	+19.01%	+12.12%	-80.63%
LIAN LianBio	+1.20%	+10.53%	+16.65%	+121.17%	+48.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.191 of 5 stars	3.5	1.0	0.0	4.7	2.6	1.7	1.3
EDIT Editas Medicine	3.8512 of 5 stars	3.2	2.0	0.0	4.2	1.4	2.5	0.6
FDMT 4D Molecular Therapeutics	2.6934 of 5 stars	3.3	3.0	0.0	0.0	3.0	1.7	0.6
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	130.88% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	121.70% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	626.18% Upside
LIAN LianBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LIAN, EDIT, FDMT, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	1.35	$0.38 per share	6.11	($0.01) per share	-231.00
EDIT Editas Medicine	$32.31M	5.49	N/A	N/A	$1.63 per share	1.30
FDMT 4D Molecular Therapeutics	$40K	4,714.08	N/A	N/A	$11.05 per share	0.37
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	4.81	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A

Latest LIAN, EDIT, FDMT, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
EDIT Editas Medicine	N/A	3.08	3.08
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
LIAN LianBio	N/A	10.06	10.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EDIT Editas Medicine	71.90%
FDMT 4D Molecular Therapeutics	99.27%
LIAN LianBio	74.85%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
EDIT Editas Medicine	2.10%
FDMT 4D Molecular Therapeutics	9.60%
LIAN LianBio	7.59%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
EDIT Editas Medicine	230	83.71 million	81.96 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable

LIAN, EDIT, FDMT, and CTMX Headlines

Recent News About These Companies

MeiraGTx Holdings PLC

May 3, 2025 | marketwatch.com

With Kezar stranded in lupus limbo, Concentra spies opportunity for next acquisition

October 9, 2024 | fiercebiotech.comF

China's Zeekr prices US IPO at top of range to raise $441 million

May 10, 2024 | msn.com

Exclusive-China's Zeekr prices US IPO at top of range to raise $441 million, source says

May 9, 2024 | msn.com

Why Is LianBio (LIAN) Stock Moving Today?

March 15, 2024 | investorplace.com

LianBio Announces Voluntarily Delisting from Nasdaq

February 28, 2024 | globenewswire.com

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

February 23, 2024 | seekingalpha.com

LianBio to shut down, return cash to investors

February 14, 2024 | biopharmadive.comB

LianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-Market

February 13, 2024 | markets.businessinsider.com

LianBio to Wind Down Operations, Declares Special Dividend

February 13, 2024 | marketwatch.com

LianBio Shares Gain After Co Announces Plans to Wind Down

February 13, 2024 | marketwatch.com

LianBio Announces Completion of Strategic Review

February 13, 2024 | finance.yahoo.com

B of A Securities Downgrades LianBio: Here's What You Need To Know

January 3, 2024 | markets.businessinsider.com

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

December 26, 2023 | markets.businessinsider.com

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

December 26, 2023 | finance.yahoo.com

Interest Is Growing for Smaller, More Speculative Names

December 20, 2023 | realmoney.thestreet.com

LianBio Announces Departure of Chief Financial Officer

December 20, 2023 | finance.yahoo.com

LianBio Names Stone as Interim CEO as Wang Resigns

December 19, 2023 | marketwatch.com

LianBio Announces Departure of Chief Executive Officer

December 19, 2023 | finance.yahoo.com

LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

December 6, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
RH Stock Rockets on Surprise Profit and Tariff Shift
By Chris Markoch | June 15, 2025
View RH Stock Rockets on Surprise Profit and Tariff Shift

LIAN, EDIT, FDMT, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.31 +0.10 (+4.52%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.01 (+0.48%)

As of 08:11 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.12 -0.07 (-3.20%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.11 -0.01 (-0.47%)

As of 08:16 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

4D Molecular Therapeutics NASDAQ:FDMT

$4.07 -0.01 (-0.25%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.10 +0.03 (+0.74%)

As of 07:47 AM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

LianBio NASDAQ:LIAN

$0.42 +0.01 (+1.20%)

As of 06/25/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time